Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611193 | 1.00 | DHFR (0.31) | DHFRNT5M | |
| SCHEMBL15427730 | 1.00 | DHFR (0.31) | DHFRNT5M | |
| SCHEMBL9611195 | 0.87 | DHFR (0.31) | DHFR | |
| SCHEMBL7859796 | 0.80 | TK1 (0.38) | DHFR | |
| SCHEMBL9611190 | 0.78 | CYP1B1 (0.42) | — | |
| SCHEMBL15427729 | 0.78 | CYP1B1 (0.42) | — | |
| SCHEMBL22984005 | 0.76 | DHFR (0.52) | DHFRNT5M | |
| SCHEMBL16964189 | 0.76 | DHFR (0.52) | DHFRNT5M | |
| SCHEMBL2431876 | 0.76 | DHFR (0.52) | DHFRNT5M | |
| SCHEMBL8514886 | 0.75 | TK1 (0.46) | DHFRNT5M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132215-B1 | COMPOUNDS FOR PREVENTING OR TREATING VIRAL INFECTIONS AND METHODS OF USE THEREOF | UNIV ALBERTA (CA) | 2015-09-23 | — | — | EP | disclosed |
| US-8633308-B2 | Compounds for preventing or treating viral infections and methods of use thereof | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20120135954-A1 | COMPOUNDS FOR PREVENTING OR TREATING VIRAL INFECTIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-05-31 | — | — | US | disclosed |
| EP-2132215-A2 | COMPOUNDS FOR PREVENTING OR TREATING VIRAL INFECTIONS AND METHODS OF USE THEREOF | The Governors of the University of Alberta (CA) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008104893-A2 | COMPOUNDS FOR PREVENTING OR TREATING VIRAL INFECTIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135954-A1 | COMPOUNDS FOR PREVENTING OR TREATING VIRAL INFECTIONS AND METHODS OF USE THEREOF | HAVCR2, MAVS, ZC3HAV1 | DHFR 1326/4885NT5M 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.